908 Devices acquires NIRLAB for $15M
The $15M upfront payment was $13M in cash and 293,368 shares of 908 Devices stock. A further $8M in stock is contingent on revenue milestones through December 31, 2027. Part of the price is held back for 12 months: $1.3M in cash and 10% of the shares, set aside to cover post-closing obligations. The deal closed May 4, 2026, and 908 Devices bought all of NIRLAB's share capital from its sellers, including the co-CEOs. The Lausanne company was founded in 2021 as a University of Lausanne spin-out and has 15 employees.
NIRLAB's handheld device identifies more than 400 drugs through plastic bags and glass. It has run over one million analyses and is sold with a mobile app and a cloud subscription for updates. The acquirer says this adds fast, high-volume screening to its trace-level detection tools. The price is about 6% of 908 Devices' roughly $265M market value. The company reported $111.7M in cash and no debt at the end of March, and it raised its 2026 revenue outlook to $67M to $70M.
For AI founders, this is a small exit for a narrow, hardware-linked product. Value came from a trained model, a growing library of identified substances, and recurring subscription revenue, packaged inside a device that law enforcement already buys. Acquirers with distribution seem willing to pay for that mix, and to push part of the price into earn-outs.
